Eurofins Scientific: Strong Cash Flows Will Fund M&A To Boost EBITDA Growth
Portfolio Pulse from
Eurofins Scientific plans to boost EBITDA growth through M&A, with strong cash flows and a confirmed 2024 outlook. The company aims for 7B EUR in revenue and adjusted EBITDA of 1.53-1.58B EUR, with plans to double net free cash flow by 2027.
January 09, 2025 | 3:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eurofins Scientific is focusing on M&A to drive EBITDA growth, with a strong 2024 outlook and plans to double net free cash flow by 2027.
Eurofins Scientific's strategy to use M&A for EBITDA growth, along with a confirmed 2024 outlook and plans to double net free cash flow, suggests positive short-term impact on stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100